Silo Pharma partners with Fireblocks for secure digital asset treasury management and infrastructure development.
Quiver AI Summary
Silo Pharma, Inc. has announced the initiation of a strategic partnership with Fireblocks, a leader in secure digital asset management, to enhance its cryptocurrency treasury management platform. This agreement enables Silo to leverage Fireblocks' institutional-grade infrastructure, which is underpinned by advanced security technologies to manage and transact digital assets effectively. CEO Eric Weisblum emphasized the value of Fireblocks' expertise in building a robust framework for Silo's treasury strategy. Silo Pharma, which focuses on developing biopharmaceuticals for underserved medical conditions, aims to integrate these digital asset capabilities into its operations while continuing research collaborations with leading institutions.
Potential Positives
- Silo Pharma has entered into a strategic agreement with Fireblocks to enhance its cryptocurrency treasury management platform, leveraging Fireblocks' expertise and advanced security infrastructure.
- The partnership with Fireblocks positions Silo Pharma to implement a more robust institutional-grade infrastructure for managing digital assets, which is critical for scaling its operations.
- Fireblocks' reputation as a globally recognized leader in the digital assets space, having facilitated over $10 trillion in secure transfers, enhances Silo's credibility in the cryptocurrency market.
Potential Negatives
- The company's description as a "diversified developmental-stage biopharmaceutical and cryptocurrency treasury company" may raise concerns about its focus and expertise in two highly complex and fast-evolving fields.
- The heavy reliance on forward-looking statements suggests significant uncertainties and risks which could impact the perceived stability and trustworthiness of the company's future prospects.
- By highlighting its status as a developmental-stage company, Silo may signal to investors that it has not yet achieved significant commercial success or market presence, potentially affecting investor confidence.
FAQ
What is Fireblocks' role in Silo Pharma's strategy?
Fireblocks is providing institutional-grade infrastructure for Silo Pharma's crypto treasury management platform.
How much digital assets has Fireblocks secured?
Fireblocks has facilitated the secure transfer of more than $10 trillion in digital assets to date.
What security features does Fireblocks offer?
Fireblocks employs a multi-layer security framework including multi-party computation and Intel SGX technology.
What is Silo Pharma's therapeutic focus?
Silo Pharma focuses on addressing conditions like stress-induced psychiatric disorders and chronic pain.
How does Silo Pharma conduct its research?
Silo Pharma conducts research in collaboration with leading universities and laboratories.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SILO Insider Trading Activity
$SILO insiders have traded $SILO stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SILO stock by insiders over the last 6 months:
- ERIC WEISBLUM (Chief Executive Officer) purchased 10,000 shares for an estimated $4,329
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SILO Hedge Fund Activity
We have seen 8 institutional investors add shares of $SILO stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADVISORSHARES INVESTMENTS LLC added 60,000 shares (+48.3%) to their portfolio in Q2 2025, for an estimated $37,800
- TWO SIGMA SECURITIES, LLC added 43,219 shares (+inf%) to their portfolio in Q2 2025, for an estimated $27,227
- RENAISSANCE TECHNOLOGIES LLC removed 37,500 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $43,875
- URSA FUND MANAGEMENT, LLC added 37,500 shares (+inf%) to their portfolio in Q2 2025, for an estimated $23,625
- XTX TOPCO LTD added 26,823 shares (+inf%) to their portfolio in Q2 2025, for an estimated $16,898
- UBS GROUP AG removed 20,085 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $23,499
- CONNING INC. removed 20,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,600
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Fireblocks is a globally recognized leader in the digital assets space, facilitating the secure transfer of more than $10 trillion to date
SARASOTA, FL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, announced that it has begun implementing its strategic agreement with Fireblocks, an enterprise platform for secure digital asset custody, settlement, trading operations, and stablecoin payments, to provide institutional-grade infrastructure for its crypto treasury management platform\.
Eric Weisblum, CEO of Silo, commented, “Fireblocks brings unmatched expertise and a proven track record to help Silo implement our treasury strategy. Together, we have begun building an institutional-grade infrastructure with the technology and safeguards needed to buy, stake, and manage digital assets at scale.”
Fireblocks is a globally recognized leader in the digital assets space, having facilitated the secure transfer of more than $10 trillion to date. Its multi-layer security framework combines multi-party computation (MPC) technology, Intel SGX, a signature policy engine, and a deposit address authentication network—delivering one of the most trusted custody solutions available to institutional clients.
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories.
silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
[email protected]
